Mydriasis Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Théa Laboratories, Omeros Corporation, Ocuphire Pharma

DelveInsight's "Mydriasis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Mydriasis, historical and forecasted epidemiology, as well as the Mydriasis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Mydriasis Market Share @ Mydriasis Market Outlook- https://www.delveinsight.com/sample-request/mydriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Mydriasis Market Report
• In January 2025, Eyenovia Inc. announced a study drug will be administered to both eyes according to a pre-specified randomization plan to determine the effect on pupil dilation. Eligible subjects will be scheduled for 2 treatment visits where either 1 mist or 2 mists of the study drug will be administered to both eyes according to a pre-specified randomization plan. Safety evaluations and efficacy measurements will be performed at specified time intervals thereafter.
• According to DelveInsight's epidemiology model, the total number of eye examinations and ophthalmic surgeries in the 7MM was approximately 352.1 million cases in 2023 which is expected to increase during the forecast period (2024-2034) due to the rise of age-related eye conditions such as cataracts, glaucoma, and macular degeneration increases, leading to more eye exams and surgeries.
• Of the total number of eye examinations and ophthalmic surgeries, eye exams and check-ups accounted for approximately 338.0 million cases in the 7MM in 2023. There were approximately 8.6 million cases of cataract surgery, 538 thousand cases of glaucoma surgery, 1.6 million cases of refractive surgery, 505 thousand cases of vitreoretinal surgery, and 2.9 million cases of other types of surgeries.
• The US accounted for 53%, while EU4 and the UK represented 32%, and Japan comprised 15% of the total cases of eye examinations and ophthalmic surgeries in 2023.
• In 2023, there were approximately 65.1 million cases of pupil dilation for eye examinations and nearly 5.1 million cases of pupil dilation for eye surgeries in EU4 and the UK.
• Among the EU4 and the UK, Germany had the highest number of pupil dilation cases for both eye examinations and surgeries in 2023, with 16.7 million and 1.5 million cases respectively followed by France with approximately 13.5 million pupil dilation cases for eye examinations and 1.3 million pupil dilation cases for ophthalmic surgeries. On the other hand, Spain had the lowest numbers, with 9.3 million pupil dilation cases for eye examinations and 634 thousand pupil dilation cases for ophthalmic surgeries.
• With a growing focus on preventive healthcare, more people will proactively seek eye exams to catch potential issues early, leading to increased dilation cases in EU4 and the UK, the total cases of dilation in eye examinations and surgeries are expected to increase.
• In Japan, there were approximately 29.7 million cases of pupil dilation for eye examinations and nearly 2.5 million cases of pupil dilation for eye surgeries in 2023. The Mydriasis epidemiology is expected to change during the forecast period.
• The leading Mydriasis Companies such as Théa Laboratories, Omeros Corporation, Ocuphire Pharma, and others.
• Promising Mydriasis Pipeline Therapies such as Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE), CTO0303-A, CTO0303-B, CTO0303-C and others.

Stay ahead in the Mydriasis Therapeutics Market with DelveInsight's Strategic Report @ Mydriasis Market Outlook- https://www.delveinsight.com/sample-request/mydriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Mydriasis Epidemiology Segmentation in the 7MM
• Total Cases of Eye Examinations and Ophthalmic Surgeries
• Total Cases of Dilation in Eye Examinations and Ophthalmic Surgeries

Download the report to understand which factors are driving Mydriasis Epidemiology trends @ Mydriasis Prevalence- https://www.delveinsight.com/sample-request/mydriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Mydriasis Marketed Drugs
• RYZUMVI (Phentolamine Ophthalmic Solution 0.75%): Viatris/Ocuphire Pharma
RYZUMVI (previously Nyxol) is an anti-microbial, preservative-free, topical eye drop formulation of phentolamine ophthalmic solution 0.75%. It is the first and only relatively non-selective alpha-1 and alpha-2 adrenergic antagonist approved to reverse pharmacologically-induced Mydriasis. The drug is administered into each dilated eye following the completion of the ophthalmic examination or procedure to reverse Mydriasis. The onset of action after administration of RYZUMVI generally occurs in 30 min, with the maximal effect seen in 60-90 min and the effect lasting at least 24 h.

• MYDCOMBI: Eyenovia
MYDCOMBI by Eyenovia is a sterile ophthalmic spray combining tropicamide (1%) and phenylephrine hydrochloride (2.5%) for pupil dilation. Designed for easy administration, it utilizes the optejet dispenser to deliver precise microdroplets, enhancing comfort and reducing overflow risks compared to traditional eye drops. MYDCOMBI is indicated for diagnostic eye examinations and short-term Mydriasis.

• OMIDRIA: Rayner Surgical/Omeros
OMIDRIA is an intra-ocular solution of phenylephrine at concentrations of 1% and 0.3%, respectively, and is prescribed for use during cataract surgery. Its primary function is to ensure that the pupil remains dilated throughout the procedure, thereby enhancing surgical visibility. Additionally, it plays a role in minimizing eye pain and reducing inflammation following surgery. This sterile solution is crucial for maintaining optimal conditions during the surgical process and promoting a smoother recovery period for patients undergoing cataract surgery.

Mydriasis Drugs Market Insights
REV-EYES (dapiprazole hydrochloride), initially approved in 1990, is an alpha-1 adrenergic antagonist used to reverse Mydriasis after eye examinations by inducing pupil constriction. Despite its initial approval in 1990, it faced discontinuation due to limited clinical benefits compared to other treatments and a lack of significant demand. In 2013, the US FDA confirmed that Rev-Eyes was not officially withdrawn, but its distribution remained scarce.

To learn more about Mydriasis treatment guidelines, visit @ Mydriasis Treatment Market Landscape- https://www.delveinsight.com/sample-request/mydriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Mydriasis Companies
Théa Laboratories, Omeros Corporation, Ocuphire Pharma, and others.

Mydriasis Market Outlook
Mydriasis, defined as the abnormal dilation of the pupils, can occur due to various factors, including pharmacological agents, neurological conditions, or trauma. The primary goal of treatment for Mydriasis is to restore the pupil to its normal size, alleviate associated symptoms such as light sensitivity and blurred vision, and address any underlying causes. The Mydriasis treatment approach is contingent upon its underlying cause. The first step in managing Mydriasis is to identify its cause.

Learn more about the FDA-approved drugs for Mydriasis @ Drugs for Mydriasis Treatment- https://www.delveinsight.com/sample-request/mydriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Mydriasis Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Mydriasis Companies- Théa Laboratories, Omeros Corporation, Ocuphire Pharma, and others.
• Mydriasis Pipeline Therapies- Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE), CTO0303-A, CTO0303-B, CTO0303-C and others.
• Mydriasis Market Dynamics: Mydriasis Market Drivers and Barriers
• Mydriasis Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Mydriasis Drugs in development @ Mydriasis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/mydriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Mydriasis Market Report Introduction
3. Mydriasis Market Overview at a Glance
4. Mydriasis Methodology of Epidemiology
5. Executive Summary
6. Key Events
7. Mydriasis Market Disease Background and Overview
8. Patient Journey
9. Mydriasis Epidemiology and Patient Population
10. Mydriasis Marketed Drugs
11. Mydriasis: Market Analysis
12. Key Opinion Leaders' Views
13. Mydriasis SWOT Analysis
14. Mydriasis Unmet Needs
15. Mydriasis Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

List of Top Selling Market Research Reports in 2025

NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Psoriasis Vulgaris Market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Immune Checkpoints Activators Market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Surgical Robotic System Market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
Diabetic Wound Market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Overactive Bladder Syndrome Market- https://www.delveinsight.com/report-store/underactive-bladder-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.